Who are KN046's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): MEDI3250.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/kn046.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

KN046 — Competitive Intelligence Brief

KN046 (KN046) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Bispecific antibody; PD-L1/4-1BB bispecific immune checkpoint modulator. Area: Oncology.

phase 3 Bispecific antibody; PD-L1/4-1BB bispecific immune checkpoint modulator PD-L1 and 4-1BB Oncology Small molecule Live · refreshed every 30 min

Target snapshot

KN046 (KN046) — Jiangsu Alphamab Biopharmaceuticals Co., Ltd. KN046 is a bispecific antibody that simultaneously engages PD-L1 on tumor cells and 4-1BB on T cells to enhance anti-tumor immune responses.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
KN046 TARGET	KN046	Jiangsu Alphamab Biopharmaceuticals Co., Ltd	phase 3	Bispecific antibody; PD-L1/4-1BB bispecific immune checkpoint modulator	PD-L1 and 4-1BB
MEDI3250	MEDI3250	AstraZeneca	phase 3	Bispecific antibody; PD-L1/4-1BB bispecific	PD-L1 and 4-1BB (CD137)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Bispecific antibody; PD-L1/4-1BB bispecific immune checkpoint modulator class)

Jiangsu Alphamab Biopharmaceuticals Co., Ltd · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). KN046 — Competitive Intelligence Brief. https://druglandscape.com/ci/kn046. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab